Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
CYRX
Cryoport, Inc.
BioStorage/BioServices-like offerings place Cryoport in the realm of diagnostics/lab services and related bioservices for samples and storage.
|
$480.64M |
$9.60
-0.93%
|
|
VREX
Varex Imaging Corporation
Core Medical Imaging category representing imaging hardware and components used in medical devices.
|
$480.15M |
$11.57
+3.26%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$474.71M |
$4.32
-2.82%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$471.40M |
$9.12
+1.05%
|
|
RXST
RxSight, Inc.
RxSight's core offering is the Light Adjustable Lens system and related ophthalmic devices used in premium cataract surgery, which fits Ophthalmology Devices.
|
$471.35M |
$11.52
+7.92%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$468.95M |
$24.17
+7.28%
|
|
KIDS
OrthoPediatrics Corp.
Directly manufactures pediatric orthopedic implants and devices (plates, screws, growing rods, braces), the core product category for the company.
|
$466.12M |
$18.58
-2.67%
|
|
ABSI
Absci Corporation
Absci's core platform is an Antibody Discovery Platform combining AI design with high-throughput wet-lab validation (lab-in-the-loop) for de novo antibody generation.
|
$462.02M |
$3.10
+0.98%
|
|
EHAB
Enhabit, Inc.
EHAB's core operations are the provision of home health and hospice services directly to patients.
|
$457.73M |
$9.04
+2.55%
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$456.29M |
$5.18
+0.78%
|
|
EOLS
Evolus, Inc.
Evolus directly produces botulinum toxin type A product (Jeuveau) used for cosmetic neuromodulation, a core injectable aesthetic treatment.
|
$455.39M |
$7.04
+0.86%
|
|
VPG
Vishay Precision Group, Inc.
Medical infusion pump design win indicates participation in the Medical Devices & Biometrics market.
|
$452.15M |
$34.13
+1.40%
|
|
MLAB
Mesa Laboratories, Inc.
Clinical Genomics hardware (MassARRAY) is diagnostic equipment used in regulated lab environments, fitting Diagnostic Equipment.
|
$442.92M |
$80.36
-1.00%
|
|
SGHT
Sight Sciences, Inc.
Directly manufactures ophthalmic surgical devices (OMNI Surgical System, TearCare-related tools) used in eye care, i.e., ophthalmology devices.
|
$439.36M |
$8.38
+3.46%
|
|
ETON
Eton Pharmaceuticals, Inc.
ETON's strategic focus on ultra-rare diseases and a portfolio of therapies for rare conditions aligns with the Biotech - Rare Diseases investable theme.
|
$434.18M |
$16.20
-0.46%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's core product is TPOXX, a small-molecule antiviral for orthopoxviruses, directly produced and marketed by the company.
|
$432.50M |
$6.05
+1.68%
|
|
STKL
SunOpta Inc.
The company functions as a co-manufacturer and private label partner, providing manufacturing services to brands and retailers.
|
$423.11M |
$3.59
+6.53%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$421.62M |
$8.23
+6.74%
|
|
AKBA
Akebia Therapeutics, Inc.
Vafseo (vadadustat) is Akebia's core product, an oral small-molecule therapeutic (HIF-PHI) for CKD anemia, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$421.58M |
$1.59
+1.27%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$417.38M |
$5.37
+4.17%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$412.68M |
N/A
|
|
CLPT
ClearPoint Neuro, Inc.
ClearPoint's core offerings include neurosurgical navigation hardware and related surgical equipment (e.g., ClearPoint system, Prism Laser Therapy, Velocity Alpha drill).
|
$410.49M |
$14.42
-1.23%
|
|
TECX
Tectonic Therapeutic, Inc.
TX45 is a recombinant fusion protein (Fc-relaxin) developed using TECX's GEODe platform, fitting the Recombinant Proteins & Enzymes category.
|
$400.25M |
$21.43
+0.85%
|
|
AURA
Aura Biosciences, Inc.
Aura's lead oncology program bel-sar is a cancer therapy, targeting solid tumors and advancing in Phase 3.
|
$396.32M |
$6.38
+4.34%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$390.86M |
$6.81
+0.15%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$390.49M |
$1.73
-0.86%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Company operates oncology-focused biotechnology with immunotherapy assets.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
iTeos Therapeutics is a biotech company focused on oncology, developing cancer immunotherapies.
|
$388.48M |
$10.15
|
|
KOPN
Kopin Corporation
CR3 medical headset and defense medical imaging/biometric sensing align with Medical Devices & Biometrics.
|
$385.85M |
$2.37
+0.21%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$383.41M |
$10.10
-0.25%
|
|
BLDE
Blade Air Mobility, Inc.
Blade's Medical segment provides healthcare logistics services including organ transport and related operations.
|
$383.21M |
$4.73
|
|
GNE
Genie Energy Ltd.
Health Insurance: Captive insurance subsidiary offering tailored health insurance products to retail customers.
|
$382.74M |
$14.30
-0.28%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
Showing page 18 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
